Aqtual Raises $16 Million in Series A Fund

Aqtual, Inc., a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, has raised $16 million in Series A financing, co-led by Genoa Ventures.

Aqtual also enrolled the first patient in PRIMA-102, a prospective clinical trial to evaluate the ability of its technology to select effective treatments for patients with rheumatoid arthritis. The multi-center trial (NCT05936970) is enrolling 150 individuals diagnosed with rheumatoid arthritis. This rapid, proof-of-concept study aims to develop a classifier capable of predicting effective drug classes for patients.

Read more in the company’s full press release.